Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (HBV). For them, the vaccine, as currently applied, has no value. Given the possible consequences of HBV infection, the number of those chronically infected with HBV presents an enormous public health challenge. For example, the major etiology of hepatocellular carcinoma (HCC) is chronic infection with HBV. Although fifth in cancer incidence, worldwide, HCC/liver cancer is the third leading cause of cancer death. The high mortality as- ciated with HCC arises because the disease is often detected late and is unresponsive to treatment. The number of deaths caused by PHCC is expected to rise over the next 20 years. Those chronically infected with HBV have a life risk of death to HCC of between 10 and 25%. Even the limited efficacy of drugs for the treatment of chronic HBV helps underscore the point that this disease is responsive to therapy. Drugs that target the polymerase (e. g. , hepsera and lamivudine) and interferon alpha represent two distinct strategies and show that both conventional antiviral and immunothe- peutic approaches can be used in management. However, the current inventory of therapeutics is inadequate. Interferon alpha is of limited value, only parenterally ava- able, and fraught with adverse reactions.
Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.
Despite the availability of an effective vaccine, there are still 400 million people worldwide who are chronically infected with the hepatitis B and D viruses (HBV and HDV), and more work still needs to be done in all of the key areas of managing the disease. In Hepatitis B and D Protocols, leading investigators and clinicians have joined forces to create a broad-ranging collection of core techniques for the study of HBV and HDV infections and for the development of therapies to treat them. In this first of two volumes Detection, Genotypes, and Characterization, the authors focus on readily reproducible molecular methods for the identification and quantification of viral markers, the detection and impact of viral variants, and the study of the viral life cycle. Each fully tested protocol is described in step-by-step detail by an established expert in the field and includes a background introduction outlining the principle underlying the technique, equipment and reagent lists, and tips on troubleshooting and avoiding known pitfalls. An accompanying second volume, Immunology, Model Systems, and Clinical Studies, contains user-friendly protocols for the study of host immune responses to infection, in vitro and in vivo models of infection, and the development of antivirals.
Taken together, Hepatitis B and D Protocols, Volume 1: Detection, Genotypes, and Characterization and Volume 2: Immunology, Model Systems, and Clinical Studies offer both new and experienced investigators an encyclopedic collection of powerful tools for studying HBV and HDV infections, as well as an essential resource for finding new therapies to treat chronically infected patients.
Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.
Da: Better World Books, Mishawaka, IN, U.S.A.
Condizione: Very Good. Former library copy. Pages intact with possible writing/highlighting. Binding strong with minor wear. Dust jackets/supplements may not be included. Includes library markings. Stock photo provided. Product includes identifying sticker. Better World Books: Buy Books. Do Good. Codice articolo GRP62879331
Quantità: 1 disponibili
Da: Basi6 International, Irving, TX, U.S.A.
Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Codice articolo ABEOCT25-173926
Quantità: 1 disponibili
Da: Basi6 International, Irving, TX, U.S.A.
Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Codice articolo ABEOCT25-173927
Quantità: 1 disponibili
Da: Romtrade Corp., STERLING HEIGHTS, MI, U.S.A.
Condizione: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Codice articolo ABBB-11272
Quantità: 1 disponibili
Da: Books Puddle, Woodside, NY, U.S.A.
Condizione: New. pp. 376 1st Edition. Codice articolo 26289296
Quantità: 4 disponibili
Da: Majestic Books, Hounslow, Regno Unito
Condizione: New. pp. 376. Codice articolo 7591375
Quantità: 4 disponibili
Da: Biblios, Frankfurt am main, HESSE, Germania
Condizione: New. pp. 376. Codice articolo 18289306
Quantità: 4 disponibili
Da: Basi6 International, Irving, TX, U.S.A.
Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Codice articolo ABEOCT25-173928
Quantità: 1 disponibili
Da: Romtrade Corp., STERLING HEIGHTS, MI, U.S.A.
Condizione: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Codice articolo ABBB-256261
Quantità: 1 disponibili
Da: moluna, Greven, Germania
Gebunden. Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (HBV). For them, the vaccine, as currently applied, has no value. Given the possible consequences of HBV infe. Codice articolo 4221403
Quantità: Più di 20 disponibili